Teva Pharmaceutical Industries (TEVA) EBITDA Margin (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted quarterly EBITDA Margin of 16.37% for Q1 2026, up 304.0% year-on-year from 4.05% in Q1 2025, and up 157.12% on a QoQ basis from 6.37% in Q4 2025.
Teva Pharmaceutical Industries (TEVA) EBITDA Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported EBITDA Margin for 18 consecutive years, with 16.37% the latest figure, recorded in Q1 2026.
- Quarterly EBITDA Margin rose 304.0% year-over-year to 16.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.19% (up 1035.0% YoY) and the FY2025 annual result came in at 12.5%, up 1433.0% from the prior year.
- EBITDA Margin rose to 16.37% in Q1 2026 per TEVA's latest filing, from 6.37% in the prior quarter.
- Over the last five years, EBITDA Margin for TEVA reached as high as 19.69% in Q3 2025 and fell as low as 25.54% in Q2 2022.
- A 5-year average of 0.58% and a median of 0.12% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 4043 bps — and 2023, when it jumped 4116 bps.
- Year by year, EBITDA Margin stood at 24.2% in 2022, then soared by 170 bps to 16.96% in 2023, then slumped by 106 bps to 1.0% in 2024, then soared by 737 bps to 6.37% in 2025, then soared by 157 bps to 16.37% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 16.37%, 6.37%, and 19.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 8.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.37% |
| Dec 31, 2025 | 6.37% |
| Sep 30, 2025 | 19.69% |
| Jun 30, 2025 | 10.90% |
| Mar 31, 2025 | 13.34% |
| Dec 31, 2024 | -1.00% |
| Sep 30, 2024 | -1.18% |
| Jun 30, 2024 | -0.12% |
| Mar 31, 2024 | -5.71% |
| Dec 31, 2023 | 16.96% |
| Sep 30, 2023 | 8.94% |
| Jun 30, 2023 | -16.86% |
| Mar 31, 2023 | -0.36% |
| Dec 31, 2022 | -24.20% |
| Sep 30, 2022 | 11.79% |
| Jun 30, 2022 | -25.54% |
| Mar 31, 2022 | -19.48% |
| Dec 31, 2021 | 1.90% |
| Sep 30, 2021 | 16.03% |
| Jun 30, 2021 | 14.88% |